Yeji

$CYTK

CYTOKINETICS INC

Runway:3 mo
NasdaqMarket cap: —CIK 0001061983

Upcoming catalysts

7 surfaced
NDA/BLA filedDate TBD
$CYTKCYTOKINETICS INC
omecamtiv mecarbil · heart failure with reduced ejection fraction (HFrEF)
“The FDA has accepted for filing the NDA for omecamtiv mecarbil based on the results from GALACTIC-HF and has assigned a Prescription Drug User Fee Act (PDUFA) date of February 28, 2023.”
AdComDate TBD
$CYTKCYTOKINETICS INC
omecamtiv mecarbil · heart failure with reduced ejection fraction (HFrEF)
“the Agency plans to convene an Advisory Committee meeting for the New Drug Application (NDA) for omecamtiv mecarbil. Cytokinetics expects the FDA to inform it of the date and topics for the Advisory Committee Meeting in a subsequent communication.”
NDA/BLA filedDate TBD
$CYTKCYTOKINETICS INC
omecamtiv mecarbil · heart failure with reduced ejection fraction (HFrEF)
“The FDA has accepted for filing the NDA for omecamtiv mecarbil based on the results from GALACTIC-HF and has assigned a Prescription Drug User Fee Act (PDUFA) date of November 30, 2022.”
NDA/BLA filedDate TBD
$CYTKCYTOKINETICS INC
omecamtiv mecarbil · heart failure with reduced ejection fraction (HFrEF)
“Cytokinetics recently announced that the U.S. Food & Drug Administration ("FDA") has accepted and filed the company's New Drug Application ("NDA") for omecamtiv mecarbil.”
AdComDate TBD
$CYTKCYTOKINETICS INC
aficamten · obstructive hypertrophic cardiomyopathy (oHCM)
“FDA has informed Cytokinetics that it does not plan to convene an advisory committee meeting to review the Company hs NDA for aficamten.”
NDA/BLA filedDate TBD
$CYTKCYTOKINETICS INC
omecamtiv mecarbil · heart failure with reduced ejection fraction (HFrEF)
“The FDA has accepted for filing the NDA for omecamtiv mecarbil based on the results from GALACTIC-HF and has assigned a Prescription Drug User Fee Act (PDUFA) date of February 28, 2023.”
NDA/BLA filedDate TBD
$CYTKCYTOKINETICS INC
aficamten · obstructive hypertrophic cardiomyopathy (oHCM)
“Cytokinetics submitted the NDA for aficamten in oHCM without an accompanying REMS, and the FDA accepted the NDA for filing.”

Drug pipeline

myqorzo
aficamten
obstructive hypertrophic cardiomyopathy (oHCM)
omecamtiv mecarbil
heart failure with reduced ejection fraction (HFrEF)
Omecamtiv Mecarbil (OM)
Heart Failure
Placebo
Amyotrophic Lateral Sclerosis
CK-1827452 24mg and 6 mg iv infusion
Heart Failure
SB-743921
Non-Hodgkin's Lymphoma
CK-3828136
Healthy Participants
Omecamtiv Mecarbil Matrix F1 Formulation
Modified Release Oral Formulation
AMG 423
Heart Failure
CK-1827452
Heart Failure
25 mg Omecamtiv Mecarbil
Heart Failure With Reduced Ejection Fraction
CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)
Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)
tirasemtiv
Amyotrophic Lateral Sclerosis (ALS)
CK-3773274 (5 - 15 mg)
Hypertrophic Cardiomyopathy (HCM)
CK-3773274 - Granules in Capsule
Symptomatic Obstructive Hypertrophic Cardiomyopathy
Reldesemtiv
Amyotrophic Lateral Sclerosis
CK-2017357
Amyotrophic Lateral Sclerosis
Ispinesib
Breast Neoplasms
Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)
Obstructive Hypertrophic Cardiomyopathy (oHCM)
CK-4021586
Healthy Participants
Aficamten (5 mg, 10 mg, 15 mg, and 20 mg)
Obstructive Hypertrophic Cardiomyopathy (oHCM)

Recent & active trials

NCTDrugPhaseStatusPrimary completion
NCT06412666Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)Phase 3Recruiting2030-01-01
NCT04848506Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)Phase 3Enrolling By Invitation2028-03-01
NCT06736574omecamtiv mecarbilPhase 3Recruiting2027-09-01
NCT04464525omecamtiv mecarbilPhase 3Withdrawn2026-11-27
NCT06793371CK-4021586Phase 2Recruiting2026-09-01
NCT06081894Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)Phase 3Active Not Recruiting2026-06-01
NCT05767346Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)Phase 3Completed2025-02-28
NCT05877053CK-4021586Phase 1Completed2024-11-20
NCT05924815Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)Phase 1Completed2023-11-14
NCT05186818Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)Phase 3Completed2023-11-10
NCT05662215CK-3828136Phase 1Terminated2023-08-08
NCT04944784ReldesemtivPhase 3Terminated2023-07-18
NCT05442775ReldesemtivPhase 3Terminated2023-06-07
NCT04219826CK-3773274 (5 - 15 mg)Phase 2Completed2023-02-28
NCT03759392omecamtiv mecarbilPhase 3Completed2021-11-08
NCT02929329omecamtiv mecarbilPhase 3Completed2020-09-14
NCT04175808omecamtiv mecarbilPhase 1Completed2020-03-04
NCT03767855CK-3773274 - Granules in CapsulePhase 1Completed2020-01-03
NCT03160898ReldesemtivPhase 2Completed2019-03-07
NCT02936635tirasemtivPhase 3Completed2018-10-26

Recent catalysts

PDUFADec 26, 2025· 162d ago· unknown
$CYTKCYTOKINETICS INC
aficamten · obstructive hypertrophic cardiomyopathy (oHCM)
“The Prescription Drug User Fee Act ("PDUFA") target action date for the NDA for aficamten remains December 26, 2025.”
FDA approvalDec 19, 2025· 169d ago· success
$CYTKCYTOKINETICS INC
myqorzo
“openFDA ORIG (TYPE 1) approval of MYQORZO — application NDA219083”
PDUFAFeb 28, 2023· 1194d ago· unknown
$CYTKCYTOKINETICS INC
omecamtiv mecarbil · heart failure with reduced ejection fraction (HFrEF)
“The New Drug Application (NDA) for omecamtiv mecarbil is currently under review by the FDA, with a Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2023.”
AdComDec 13, 2022· 1271d ago
$CYTKCYTOKINETICS INC
omecamtiv mecarbil · heart failure with reduced ejection fraction (HFrEF)
“Cytokinetics, Incorporated today announced that the U.S. Food & Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 8 to 3 that the benefits of omecamtiv mecarbil do not outweigh its risks for the treatment of heart failure with reduced ejection fraction (HFrEF).”
PDUFANov 30, 2022· 1284d ago· unknown
$CYTKCYTOKINETICS INC
omecamtiv mecarbil · heart failure with reduced ejection fraction (HFrEF)
“The FDA has assigned the NDA a standard review with a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2022.”
NDA/BLA filedFeb 4, 2022· 1583d ago· unknown
$CYTKCYTOKINETICS INC
omecamtiv mecarbil · heart failure with reduced ejection fraction (HFrEF)
“Today, February 4, 2022, Cytokinetics, Incorporated (the ”